Literature DB >> 9489813

Longterm prospective study of methotrexate in rheumatoid arthritis: conclusion after 132 months of therapy.

M E Weinblatt1, A L Maier, P A Fraser, J S Coblyn.   

Abstract

OBJECTIVE: To conclude observations of efficacy of longterm methotrexate (MTX) treatment of rheumatoid arthritis (RA).
METHODS: Twenty-six patients with RA entered a prospective study of MTX in 1983. The study was completed after 132 months of therapy.
RESULTS: Significant improvement (p < 0.001) was noted in the number of painful joints, swollen joints, and physician and patient global assessments. There was 50% improvement in the joint pain index and joint swelling index in > 65% of the patients. A significant reduction in prednisone dose was achieved. Sixteen patients withdrew from the study. Toxicity led to 3 drug related withdrawals of study patients (alopecia 1; pneumonitis 2). At 132 months, 10 patients (38%) had completed the study; 3 patients (11%) discontinued due to MTX toxicity.
CONCLUSION: MTX was an effective treatment for RA in this 132 month prospective study.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9489813

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  24 in total

Review 1.  The treatment of rheumatoid arthritis: a review of recent clinical trials.

Authors:  T Mikuls; L Moreland
Journal:  Curr Rheumatol Rep       Date:  1999-12       Impact factor: 4.592

Review 2.  "Stepping-up" from methotrexate: a systematic review of randomised placebo controlled trials in patients with rheumatoid arthritis with an incomplete response to methotrexate.

Authors:  M C Hochberg; J K Tracy; R H Flores
Journal:  Ann Rheum Dis       Date:  2001-11       Impact factor: 19.103

Review 3.  Comparison of the efficacy of the tumour necrosis factor alpha blocking agents adalimumab, etanercept, and infliximab when added to methotrexate in patients with active rheumatoid arthritis.

Authors:  M C Hochberg; J K Tracy; M Hawkins-Holt; R H Flores
Journal:  Ann Rheum Dis       Date:  2003-11       Impact factor: 19.103

4.  The effect of low-dose methotrexate on bone mineral density in patients with early rheumatoid arthritis.

Authors:  Funda Tascioglu; Cengiz Oner; Onur Armagan
Journal:  Rheumatol Int       Date:  2003-03-21       Impact factor: 2.631

5.  Investigating methotrexate toxicity within a randomized double-blinded, placebo-controlled trial: Rationale and design of the Cardiovascular Inflammation Reduction Trial-Adverse Events (CIRT-AE) Study.

Authors:  Jeffrey A Sparks; Medha Barbhaiya; Elizabeth W Karlson; Susan Y Ritter; Soumya Raychaudhuri; Cassandra C Corrigan; Fengxin Lu; Jacob Selhub; Daniel I Chasman; Nina P Paynter; Paul M Ridker; Daniel H Solomon
Journal:  Semin Arthritis Rheum       Date:  2017-02-10       Impact factor: 5.532

Review 6.  Methotrexate in rheumatoid arthritis: a quarter century of development.

Authors:  Michael E Weinblatt
Journal:  Trans Am Clin Climatol Assoc       Date:  2013

7.  Factors associated with toxicity, final dose, and efficacy of methotrexate in patients with rheumatoid arthritis.

Authors:  M Hoekstra; A E van Ede; C J Haagsma; M A F J van de Laar; T W J Huizinga; M W M Kruijsen; R F J M Laan
Journal:  Ann Rheum Dis       Date:  2003-05       Impact factor: 19.103

8.  Compliance with methotrexate treatment in patients with rheumatoid arthritis: influence of patients' beliefs about the medicine. A prospective cohort study.

Authors:  Annette de Thurah; Mette Nørgaard; Ingegerd Harder; Kristian Stengaard-Pedersen
Journal:  Rheumatol Int       Date:  2009-10-13       Impact factor: 2.631

9.  Methotrexate related adverse effects in patients with rheumatoid arthritis are associated with the A1298C polymorphism of the MTHFR gene.

Authors:  Y Berkun; D Levartovsky; A Rubinow; H Orbach; S Aamar; T Grenader; I Abou Atta; D Mevorach; G Friedman; A Ben-Yehuda
Journal:  Ann Rheum Dis       Date:  2004-10       Impact factor: 19.103

Review 10.  Methotrexate for treating rheumatoid arthritis.

Authors:  Maria Angeles Lopez-Olivo; Harish R Siddhanamatha; Beverley Shea; Peter Tugwell; George A Wells; Maria E Suarez-Almazor
Journal:  Cochrane Database Syst Rev       Date:  2014-06-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.